Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
BioCryst Pharmaceuticals clinical trials
The registry lists 74 studies whose lead sponsor is BioCryst Pharmaceuticals or one of 2 companies grouped under it. 4 are recruiting or about to start. Per ClinicalTrials.gov, last updated Aug 27, 2026.
Keep track of what changes. Save the BioCryst Pharmaceuticals studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to BioCryst Pharmaceuticals.
- BioCryst Pharmaceuticals54 studiesSame company
Something wrong?
- Catabasis Pharmaceuticals13 studies →Acquired — became part of BioCryst Pharmaceuticals, Jan 23, 2026 · source ↗
Something wrong?
- Astria Therapeutics, Inc.7 studies →Acquired — became part of BioCryst Pharmaceuticals, Jan 23, 2026 · source ↗
Something wrong?
Focus areas
Conditions BioCryst Pharmaceuticals leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 74. Browse all 74 →
- A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725RecruitingNCT06539507Phase 1
- A Long-Term Study of Navenibart in Participants With Hereditary AngioedemaEnrolling by invitationNCT07204938Phase 3
Sponsor listed in the registry: Astria Therapeutics, Inc. · First submitted before Astria Therapeutics, Inc. became part of BioCryst Pharmaceuticals
- A Trial to Compare the Pharmacokinetics of Two Presentations of Navenibart in Healthy ParticipantsRecruitingNCT07635095Phase 1
Sponsor listed in the registry: Astria Therapeutics, Inc. · First submitted after Astria Therapeutics, Inc. became part of BioCryst Pharmaceuticals
- Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat StudiesEnrolling by invitationNCT04933721Phase 3
- A Study of Navenibart in Participants With Hereditary AngioedemaActive, not recruitingNCT06842823Phase 3
Sponsor listed in the registry: Astria Therapeutics, Inc. · First submitted before Astria Therapeutics, Inc. became part of BioCryst Pharmaceuticals
- A Study to Evaluate the Efficacy and Safety of Intravenous Peramivir in Subjects With Uncomplicated Influenza.WithdrawnNCT01224795Phase 3
- Intramuscular Peramivir for the Treatment of Uncomplicated InfluenzaWithdrawnNCT00486980Phase 3
- A Study of Avoralstat In Participants With Diabetic Macular EdemaTerminatedNCT07228559Phase 1
- A Study of Navenibart (STAR-0215) in Participants With Hereditary AngioedemaCompletedNCT05695248Phase 1/2
Sponsor listed in the registry: Astria Therapeutics, Inc. · First submitted before Astria Therapeutics, Inc. became part of BioCryst Pharmaceuticals
- Berotralstat Treatment in Children With Hereditary AngioedemaActive, not recruitingNCT05453968Phase 3
- 12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE AttacksCompletedNCT02303626Phase 2/3
- A Study of STAR-0310 in Healthy Adult ParticipantsActive, not recruitingNCT06782477Phase 1
Sponsor listed in the registry: Astria Therapeutics, Inc. · First submitted before Astria Therapeutics, Inc. became part of BioCryst Pharmaceuticals
- Long-term Safety of BCX9930 in Participants With Paroxysmal Nocturnal HemoglobinuriaTerminatedNCT05741346Phase 2
- A Long-term Study of STAR-0215 in Participants With Hereditary AngioedemaActive, not recruitingNCT06007677Phase 2
Sponsor listed in the registry: Astria Therapeutics, Inc. · First submitted before Astria Therapeutics, Inc. became part of BioCryst Pharmaceuticals
- A Long-Term Safety Study of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)TerminatedNCT04702568Phase 2
- BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants With Inadequate Response to C5 Inhibitor TherapyTerminatedNCT05116774Phase 2
- Dose Escalation of BCX10013 in Participants with Paroxysmal Nocturnal Hemoglobinuria (PNH)CompletedNCT06100900Phase 1
- BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants Not Receiving Other Complement Inhibitor TherapyTerminatedNCT05116787Phase 2
- Study to Evaluate the Efficacy and Safety of BCX7353 as an Oral Treatment for the Prevention of HAE Attacks in JapanCompletedNCT03873116Phase 3
- Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN)TerminatedNCT05162066Phase 2
- A Study of STAR-0215 in Healthy Adult ParticipantsCompletedNCT05477160Phase 1
Sponsor listed in the registry: Astria Therapeutics, Inc. · First submitted before Astria Therapeutics, Inc. became part of BioCryst Pharmaceuticals
- Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAECompletedNCT03485911Phase 3
- A Long Term Safety Study of BCX7353 in Hereditary AngioedemaCompletedNCT03472040Phase 2/3
- Phase 1/2 Study in Boys With Duchenne Muscular DystrophyCompletedNCT02439216Phase 1/2
Sponsor listed in the registry: Catabasis Pharmaceuticals · First submitted before Catabasis Pharmaceuticals became part of BioCryst Pharmaceuticals
- Phase III Study of Edasalonexent in Boys With Duchenne Muscular DystrophyCompletedNCT03703882Phase 3
Sponsor listed in the registry: Catabasis Pharmaceuticals · First submitted before Catabasis Pharmaceuticals became part of BioCryst Pharmaceuticals
- First-in-Human Study of BCX9930 in Healthy Volunteers and Patients With PNHCompletedNCT04330534Phase 1/2
- A Study to Evaluate the Single Dose Safety, Tolerability and Pharmacokinetics of IV BCX4430CompletedNCT03800173Phase 1
- A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19TerminatedNCT03891420Phase 1
- Study of BCX7353 as a Treatment for Attacks of Hereditary AngioedemaCompletedNCT03240133Phase 2
- Efficacy and Safety of BCX7353 to Prevent Angioedema Attacks in Subjects With Hereditary AngioedemaCompletedNCT02870972Phase 2
- Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated InfluenzaCompletedNCT02635724Phase 3
- Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Subjects With Uncomplicated InfluenzaCompletedNCT02369159Phase 3
- Intramuscular Peramivir in Subjects With Uncomplicated Acute InfluenzaTerminatedNCT00610935Phase 3
- Study of Edasalonexent With Midazolam and Deflazacort in Healthy SubjectsCompletedNCT04543370Phase 1
Sponsor listed in the registry: Catabasis Pharmaceuticals · First submitted before Catabasis Pharmaceuticals became part of BioCryst Pharmaceuticals
- A 2-Part, Phase 1, Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CAT-2054 in Healthy SubjectsCompletedNCT02374047Phase 1
Sponsor listed in the registry: Catabasis Pharmaceuticals · First submitted before Catabasis Pharmaceuticals became part of BioCryst Pharmaceuticals
- Oral Berotralstat Expanded Access ProgramApproved for marketingNCT04428632
- An Open-Label Extension Study of Edasalonexent in Boys With Duchenne Muscular DystrophyTerminatedNCT03917719Phase 3
Sponsor listed in the registry: Catabasis Pharmaceuticals · First submitted before Catabasis Pharmaceuticals became part of BioCryst Pharmaceuticals
- A Relative Bioavailability Study of Two Formulations of BCX7353CompletedNCT03202784Phase 1
- A Drug-Drug Interaction Study to Evaluate Drug Transporter InteractionsCompletedNCT03136237Phase 1
- A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With HypercholesterolemiaCompletedNCT02608697Phase 2
Sponsor listed in the registry: Catabasis Pharmaceuticals · First submitted before Catabasis Pharmaceuticals became part of BioCryst Pharmaceuticals
- An Open-label Drug-Drug Interaction Study to Evaluate the Effect of BCX7353 on Cytochrome P450 Enzyme Activity Using Probe SubstratesCompletedNCT02819102Phase 1
- Pilot Study To Assess CAT-2003 in Patients With HyperlipidemiaCompletedNCT01912560Phase 2
Sponsor listed in the registry: Catabasis Pharmaceuticals · First submitted before Catabasis Pharmaceuticals became part of BioCryst Pharmaceuticals
- Pilot Study To Assess CAT-2003 in Patients With ChylomicronemiaCompletedNCT02098278Phase 2
Sponsor listed in the registry: Catabasis Pharmaceuticals · First submitted before Catabasis Pharmaceuticals became part of BioCryst Pharmaceuticals
- A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BCX4430CompletedNCT02319772Phase 1
- Open-label, Long-term Safety Study of Avoralstat in Subjects With Hereditary AngioedemaTerminatedNCT02670720Phase 3
- First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BCX7353 in Healthy Western and Japanese VolunteersCompletedNCT02448264Phase 1
- Pilot Study To Assess CAT-2003 in Patients With Severe HypertriglyceridemiaCompletedNCT01968720Phase 2
Sponsor listed in the registry: Catabasis Pharmaceuticals · First submitted before Catabasis Pharmaceuticals became part of BioCryst Pharmaceuticals
- A Phase II, Multicenter, Randomized, Placebo -Controlled, Study To Evaluate The Efficacy and Safety Of Intramuscular Peramivir 600 mg In Subjects With Uncomplicated Acute InfluenzaCompletedNCT00705406Phase 2
- A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to InfluenzaTerminatedNCT00958776Phase 3
- Evaluation of the Efficacy and Safety of Peramivir in Subjects With Uncomplicated Acute Influenza.CompletedNCT00419263Phase 2